Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo? Eur J Nucl Med Mol Imaging (2004) 0.78

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56

Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09

Alzheimer's disease is a synaptic failure. Science (2002) 13.82

Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83

Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73

Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging (1997) 7.54

Alzheimer's disease. N Engl J Med (2004) 7.50

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46

Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. Neurobiol Aging (2004) 5.68

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75

In-vivo measurement of activated microglia in dementia. Lancet (2001) 3.51

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80

In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology (1999) 1.86

PET imaging of amyloid in Alzheimer's disease. Lancet Neurol (2004) 1.55

Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42

A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl (2003) 1.29

Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging (1995) 1.11

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am (2003) 1.07

Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J Neurosci (2003) 0.93

Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging (2002) 0.92

Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains--in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord (1995) 0.87

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol (2003) 0.87

Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol (1995) 0.82